Core Viewpoint - China Traditional Chinese Medicine (00570.HK) reported a significant decline in mid-term performance for the six months ending June 30, 2025, with revenue of approximately RMB 7.46 billion, a year-on-year decrease of 11.0% and a loss of RMB 142 million, marking a substantial drop in basic earnings per share to RMB -0.0214, down 151.1% from RMB 0.0419 in the same period last year [1][1][1] Revenue Performance - The decline in sales revenue is primarily attributed to the increased proportion of traditional Chinese medicine formula granules in the collective procurement business and intensified market competition [1][1][1] - The company is actively promoting structural optimization in its operations, focusing on the development of advantageous varieties and local products, while strategically reducing low-margin and high-risk businesses, which has contributed to the decrease in revenue [1][1][1] Business Strategy - The company has paused certain homogenized and non-competitive product lines and businesses within the traditional Chinese medicine health sector, leading to a further decline in revenue during the reporting period [1][1][1]
中国中药(00570.HK)中期营业额约74.6亿元 同比减少11.0%